Isbn: 9783725856237 - management of dyslipidaemias: enhancing lipid modification to reduce cardiovascular risk (15 resultados)

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.

Condición: New.

Hardback. Condición: New.

Hardback. Condición: New.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: New. Print on Demand.

Condición: New. Print on Demand.

Condición: New. PRINT ON DEMAND.

Hardcover. Condición: new. Hardcover. Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmental, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Cardiovascular disease remains a leading cause of death worldwide, with low-density lipoproteins and other atherogenic lipoproteins, such as lipoprotein remnants, playing a key role in the development of atherosclerosis. Beyond LDL cholesterol, the identification of biological, environmental, and genetic markers associated with remnant metabolism has improved cardiovascular risk prediction and informed treatment strategies. This Reprint examines rare and severe lipid disorders, including homozygous familial hypercholesterolemia, refractory hypercholesterolemia, and severe hypertriglyceridemia, which continue to present major therapeutic challenges despite maximally tolerated lipid-lowering therapies. It also highlights the rapid development of novel inhibitors such as PCSK9, ANGPTL3, and APOC3, as well as emerging therapies derived from new mechanistic pathways. In addition, the link between metabolic conditions such as non-alcoholic steatohepatitis and cardiovascular events is explored. Collectively, the articles in this Reprint provide a comprehensive and up-to-date overview of current advances, ongoing challenges, and future perspectives in lipid modification and cardiovascular risk management.…

Buch. Condición: Neu. Management of Dyslipidaemias | Enhancing Lipid Modification to Reduce Cardiovascular Risk | Buch | Englisch | 2025 | MDPI AG | EAN 9783725856237 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.…